During the past decade, Tosei General Hospital conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 14 clinical trials were completed, i.e. on average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 10 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tosei General Hospital" #1 sponsor was "Boehringer Ingelheim" with 12 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Galapagos NV" with 2 trials sponsored, "Actelion" with 1 trials sponsored and "Chugai Pharmaceutical" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tosei General Hospital" #1 collaborator was "NPO International TRI Network" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Japan Lung Cancer Society" with 1 trials as a collaborator and "Ministry of Health, Labour and Welfare, Japan" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Tosei General Hospital" are "Idiopathic Pulmonary Fibrosis" (11 trials), "Lung Diseases, Interstitial" (4 trials), "Acute Myocardial Infarction" (1 trials), "Atrial Fibrillation" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Tosei General Hospital" in a lesser frequency.

Most popular intervention types in "Tosei General Hospital" are "Drug" (20 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Nintedanib" (6 trials), "BI 1015550" (3 trials), "GLPG1690" (2 trials) and "PRM-151 (Zinpentraxin Alfa)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Tosei General Hospital" are 25 trials for "All" genders.

Currently, there are NaN active trials in "Tosei General Hospital". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Tosei General Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Tosei General Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".